Mutations in the microtubule-associated protein tau gene (MAPT) cause frontotemporal dementia with parkinsonism linked to chromosome 17 . 1 In addition, the major common MAPTcontaining H1 haplotype is associated with increased risk for 2 parkinsonian disorders: progressive supranuclear palsy (PSP) characterized by 4-repeat tau pathology and Parkinson disease (PD) with ␣-synuclein pathology. 2,3 However, the role of MAPT variation in other disorders with similar pathology or disease phenotype is unclear. We investigated the frequency of the MAPT H1 haplotype in both essential tremor (ET) and multiple system atrophy (MSA).
Mutations in the microtubule-associated protein tau gene (MAPT) cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). 1 In addition, the major common MAPTcontaining H1 haplotype is associated with increased risk for 2 parkinsonian disorders: progressive supranuclear palsy (PSP) characterized by 4-repeat tau pathology and Parkinson disease (PD) with ␣-synuclein pathology. 2, 3 However, the role of MAPT variation in other disorders with similar pathology or disease phenotype is unclear. We investigated the frequency of the MAPT H1 haplotype in both essential tremor (ET) and multiple system atrophy (MSA).
ET is the most common movement disorder, and prior evidence has indicated a common link between ET and PD from clinical, epidemiologic, and pathologic studies as well as some reports of brainstem Lewy bodies at autopsy in patients with ET. 4 MSA is a neurodegenerative disorder with ␣-synuclein pathology with a mixed clinical presentation combining autonomic dysfunction, parkinsonism, and cerebellar or pyramidal symptoms. The initial clinical signs of MSA with prominent parkinsonism can make it difficult to differentially diagnose it from early PD. In addition, up to 30% of patients with MSA with prominent parkinsonism may have a transient response to levodopa therapy. 5 Methods. Genotyping of the MAPT H1 discriminating SNP (rs1052553) and H1c subhaplotype SNP (rs242557) was performed on a Sequenom MassArray iPLEX platform (San Diego, CA) (primer sequences are available on request) and analyzed with Typer 4.0 software. The rate of genotype calls was Ն95% in each population. The series contained 356 patients with clinical ET, 61 patients with pathologically confirmed MSA, and 409 US control subjects; all samples are North American Caucasians. Numerical variables were summarized with the sample mean, SD, and range (table e-1 on the Neurology ® Web site at www.neurology.org). Associations between ET and MSA with MAPT rs1052553 and rs242557 were measured by 2 statistics with Pearson probability estimates and corresponding odds ratios (ORs) with confidence intervals (CIs).
Standard protocol approvals, registrations, and patient
consents. The ethical review boards at each institution approved the study, and all participants provided informed consent.
Results.
We observed an uncorrected association of MAPT H1 genotype with both ET ( p ϭ 0.027) and MSA ( p ϭ 0.016) when compared to the frequency in controls ( Discussion. Given the relatively small sample size for both the ET and MSA series, and the possible clinical overlap with PD in the ET series, these results must be treated with caution and require independent replication. However, it is intriguing that while the extended haplotype containing MAPT has now shown association with a number of parkinsonian disorders, there is no evidence of association with AD, which displays abundant tau pathology. Given the presence of ␣-synuclein pathology in PD, MSA, and ET, these findings indicate a possible interplay between these proteins. It has been previously suggested that ␣-synuclein induces fibrillization of tau and that coincubation of tau and ␣-synuclein synergistically promotes fibrillization of both proteins. 7 While we observed an association between the MAPT H1 haplotype and both ET and MSA, the functional variant remains to be identified. The expanded H1 haplotype contains MAPT, which is the best candidate gene to explain the observed association; however, other genes are present in this haplotype that cannot be excluded. It is postulated that the alternate MAPT haplotypes affect a differential expression of 3-repeat and 4-repeat tau protein in FTDP-17. 2 The SNP displaying the strongest association with risk of the tauopathy PSP (rs242557) does not show the same association with PD, MSA, or Supplemental data at www.neurology.org ET, suggesting different pathomechanisms for disease risk. 2, 6 It is now crucial to determine the functional risk variants that are located on the backbone of the extended H1 haplotype containing MAPT. With the established genomic capture and next-generation sequencing approaches, this goal is within reach. Sequencing of the entire extended haplotype will identify the variants influencing risk of PSP, PD, MSA, or ET, and help elucidate the disease pathways involved. LRRK2. Dr. Ross serves on the editorial board of Open Longevity Science.
TUMEFACTIVE DEMYELINATION, AN UNCOMMON FORM OF TACROLIMUS NEUROTOXICITY
The immunosuppressant tacrolimus (FK 506) is widely used in transplantation medicine, although it has neurotoxic side effects. The neurotoxicity of tacrolimus to the CNS consists mainly of leukoencephalopathy with clinical and radiologic features similar to posterior reversible encephalopathy syndrome (PRES). 1 The neurologic symptoms and signs of leukoencephalopathy usually develop within 3 months of commencing treatment with tacrolimus. 1 We describe a patient who developed tumefactive inflammatory demyelinating lesions as an atypical manifestation of tacrolimus neurotoxicity.
Case report.
A 54-year-old woman with hepatocellular carcinoma underwent cadaver liver transplantation in May 2009. After transplantation, she was treated with tacrolimus 0.075 mg/kg and mycophenolate mofetil 250 mg BID. In September 2009, she developed slurred speech and right-side weakness 2 days before admission. Brain MRI scanned 2 days after symptoms onset showed 2 large mass-like lesions in the left corona radiata and frontal lobe. The lesions were hyperintense on T2-weighted images with an open ring pattern on gadolinium enhancement ( figure, A) . The serum tacrolimus level was 8.5 ng/mL (therapeutic range 5.0 -15.0 ng/mL). The CSF analysis showed normal cell count, but elevated total protein level (103 mg/dL). Oligoclonal bands were absent and immunoglobulin G index was within normal range. The laboratory investigations for viruses including JC virus, Epstein-Barr virus, herpes simplex virus, cytomegalovirus, and other infections such as tuberculosis, mycoses, and parasites in the CSF and serum were all negative.
Her symptoms worsened over the next 3 days and she developed right hemiplegia, motor aphasia, and altered mental status. As we could not rule out the possibility of post-transplant malignancy or opportunistic infection such as progressive multifocal leukoencephalopathy (PML), though the mode of manifestation was not compatible, we performed an open craniotomy for excisional biopsy of the left frontal mass. Interestingly, the neuropathologic examination showed acute inflammatory demyelination with no evidence of tumor cells or PML (figure, C).
Hypothesizing that tacrolimus induced the demyelinating lesions, the tacrolimus was discontinued immediately and high-dose steroids were initiated. Over the following weeks, maintained on mycophenolate mofetil only, her symptoms gradually improved, although the hemiparesis remained. Follow-up MRI obtained 8 months later showed a marked reduction in the extent of the lesions and no new lesions were seen (figure, B).
Discussion.
Our patient showed several characteristics distinct from reported CNS neurotoxicity caused by tacrolimus. First, she had focal mass-like lesions mimicking a brain tumor or abscess. Second, the pathology of brain biopsy revealed acute inflammatory demyelination. Finally, the symptoms occurred relatively late, nearly 5 months after starting the tacrolimus treatment. These findings suggested that the underlying pathomechanism of lesion formation in our patient differed from that of reported tacrolimus neurotoxicity.
The pathomechanism of tacrolimus-induced CNS neurotoxicity remains unclear. Some studies have suggested that extracellular edema with endothelial damage caused by tacrolimus explains the S.H. Kim, MD W. Kim, MD, PhD K.W. Lee, MD, PhD E.K. Hong, MD, PhD H.J. Kim, MD, PhD acute occurrence of PRES-like leukoencephalopathy and the reversibility of the clinical and radiologic abnormalities. 2 High serum tacrolimus levels have been correlated with neurotoxicity in some, but not all, reports. 1, 2 Although the serum tacrolimus level in our patient was normal (8.5 ng/mL) at the onset of her symptoms, her neurologic symptoms worsened when she was maintained on tacrolimus, and then gradually improved after discontinuing the tacrolimus.
Tacrolimus is an immunosuppressive agent that inhibits calcineurin, a calcium-dependent protein phosphatase, and causes a decrease in interleukin-2 synthesis and T-cell proliferation via downstream effects. 3 It has been reported that tacrolimus protects against demyelination and axonal loss in experimental autoimmune encephalitis (EAE) and chronic inflammatory demyelinating polyneuropathy (CIDP) through immunosuppression and neuroprotection. 4, 5 However, previous studies on the effects of tacrolimus also have reported conflicting findings. Low doses of cyclosporine A, which has a mechanism of action similar to tacrolimus, induced unexpected exacerbation of inflammatory demyelination in EAE. 6 In addition, CIDP is reported to be associated with tacrolimus. 7 Possible mechanisms that may explain the immune-mediated demyelination by calcineurin inhibitors include enhanced T-cell activation or failure to inhibit T-cell activation in response to myelin, and alteration in T-cell subsets resulting in elevated T-cells reacting with myelin. 3, 7 However, the exact mechanism of 2 different effects of tacrolimus, beneficial or deleterious, on nervous system is unknown. The degree of immunosuppression that is mainly decided by drug dosage, time to treatment in relation to disease course, and variable host factors may determine whether tacrolimus causes nerve damage. 6 Our case suggests that tumefactive demyelination should be considered an uncommon form of neurotoxicity caused by tacrolimus and provides the first neuroimaging and pathologic evidence of this. 
